✦ LIBER ✦

Has “levodopa-induced neuropathy” been reported in Parkinson's disease clinical trials?

✍ Scribed by Tiago Teodoro; Daniela Pires; Mário M. Rosa; Miguel Coelho; Cristina Sampaio; Joaquim J. Ferreira

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 573 KB
Volume: 26
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.23760

No coin nor oath required. For personal study only.

✦ Synopsis

The disorders of voice and speech in Parkinson's disease (PD) result from involvements in several subsystems including respiration, phonation, articulation, and prosody. [1][2][3] We investigated the feasibility of acoustic measures for the identification of voice and speech disorders in PD, using a quick vocal test consisting of sustained phonation, diadochokinetic task, and running speech. Various traditional and novel acoustic measurements have been designed in order to be gender independent, represent all speech subsystems, reduce the time required for voice investigation, and provide a reliable automated assessment in practice. 4

📜 SIMILAR VOLUMES

Levodopa-induced belly dancer's dyskines

Levodopa-induced belly dancer's dyskinesias in Parkinson's disease: Report of one case

✍ Miryam Carecchio; Alessandra Collini; Cristoforo Comi; Roberto Cantello; Kailash 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

Levetiracetam for levodopa-induced dyski

Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial

✍ Martin Wolz; Matthias Löhle; Karl Strecker; Uta Schwanebeck; Christine Schneider 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 255 KB

Use of the new levodopa agent Stalevo (l

Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial)

✍ A. N. Boiko; T. T. Batysheva; N. G. Minaeva; L. A. Babina; T. V. Vdovichenko; E. 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 200 KB

The need for levodopa as an end point of

The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol

✍ Dr. Peter LeWitt; David Oakes; Lu Cui 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 693 KB

## Abstract Progression of Parkinson's disease (PD) can be detected through changes in clinical ratings or disability assessments. A clinical trial, Deprenyl and Alpha‐Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), used a novel study end point: increase in parkinsonian disability to th

An open-label, multicentre clinical tria

An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease

✍ M. M. Pinter; A. W. F. Rutgers; E. Hebenstreit; on behalf of the the study cente 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 198 KB